Not FDA-Approved (Reclassification Pending)Growth Hormone

GHRP-6

Also known as: Growth Hormone Releasing Peptide-6, Growth Hormone Releasing Hexapeptide

One of the earliest synthetic growth hormone releasing peptides. Known for its strong GH-releasing effect and its very noticeable appetite stimulation. Less selective than newer options like ipamorelin, meaning it also raises cortisol and prolactin. Expected to return to legal compounding in 2026.

How it works

GHRP-6 is a synthetic hexapeptide that activates the ghrelin receptor in the pituitary gland, causing a strong pulse of growth hormone release. It also acts on hypothalamic neurons to powerfully stimulate appetite, more so than any other GHRP. It works best when stacked with a GHRH analog for maximum GH output.

Common uses

Side effects

Key research

Safety notes

  • Not FDA-approved for any human therapeutic use
  • Was placed on FDA Category 2 restricted list in 2023-2024
  • Among the 14 peptides expected to return to Category 1 per February 2026 HHS announcement
  • Raises cortisol more than ipamorelin, which can affect sleep, mood, and blood sugar
  • No pharmaceutical-grade product exists. Quality varies between suppliers
  • Requires metabolic and hormonal monitoring under medical supervision

Too many clinics, not enough clarity?

We don't sell peptides. Tell us your goals and we'll connect you with a vetted provider who can figure out what actually makes sense for you.

See what's right for you

Explore other peptides